Urinary incontinence (UI) is the subject of a new study from Decision Resources, Inc., that examines the commercial potential of emerging drugs to treat this condition in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) over a 2000-2010 forecast period.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

The first major pharmacological breakthroughs in UI in two decades- tolterodine (Pharmacia's Detrol), and extended-release oxybutynin (Alza's Ditropan XL)-have enlivened commercial interest in the UI market, especially the market for overactive bladder therapies. Tolterodine has fared particularly well in the United States. However, the drug will face stiff competition from Ditropan XL-a drug that has, in its own right, enjoyed considerable growth: 156% between 1999 and 2000 in the United States, according to company reports.

Both Pharmacia and Alza have initiated direct-to-consumer advertising campaigns to bolster their stakes in the growing market for UI products. These efforts will alert patients and physicians to the availability of improved therapies, increasing the number of patients seeking medical treatment. Pharmacia is placing its future hopes on an extended-release formulation of tolterodine; Alza is counting on its own extended-release formulation of Ditropan. To keep pace in an increasingly competitive anticholinergic market, Pharmacia will have to show that extended-release tolterodine is at least comparable to Ditropan XL. Both agents may face a major challenge from Pfizer's darifenacin by 2010. If darifenacin holds true to its heightened selectivity and improved side-effect profile, this novel agent will begin to steal market share from other anticholinergic drugs.

Urinary Incontinence offers invaluable market intelligence for pharmaceutical companies developing drugs to treat this indication. This study is part of Mosaic, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or sama@dresources.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or fbidart@decisionresources.be. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp.


NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,

Decision Resources Study on Parkinson's Disease Forecasts Significant Commercial Opportunities for Drugs that Delay the Use of Levodopa

View Now